Welcome to our dedicated page for Pliant Therapeutics news (Ticker: PLRX), a resource for investors and traders seeking the latest updates and insights on Pliant Therapeutics stock.
Pliant Therapeutics, Inc. (Nasdaq: PLRX) is a clinical-stage biopharmaceutical company focused on integrin-based therapeutics for fibrotic diseases, solid tumors and muscular dystrophies. This news page aggregates company-issued updates and market-moving announcements so readers can follow how Pliant’s clinical programs and corporate strategy evolve over time.
In its recent press releases, Pliant has highlighted several key themes. The company has reported interim and ongoing data from a Phase 1, open-label, dose-escalation trial of PLN-101095, an oral dual-selective inhibitor of integrins αvβ8 and αvβ1, in patients with advanced or metastatic solid tumors that are resistant or refractory to immune checkpoint inhibitors. These updates describe antitumor activity, including partial and complete responses in certain dose cohorts when PLN-101095 is combined with pembrolizumab, as well as safety and pharmacokinetic observations.
Pliant’s news flow has also covered developments in its bexotegrast (PLN-74809) program in idiopathic pulmonary fibrosis, including the termination and close-out of the BEACON-IPF Phase 2b/3 trial and the company’s decision to discontinue development of bexotegrast in IPF after reviewing safety and efficacy data. Additional communications have described scientific presentations at medical conferences, such as the American Thoracic Society International Conference, where the company has shared clinical and preclinical data related to fibrosis and biomarkers.
Corporate updates, including workforce and operational realignments, financial results and changes in executive roles, are also part of Pliant’s news record. Investors and followers of PLRX can use this page to review these categories of news—clinical trial updates, scientific presentations, program decisions and corporate announcements—in one place and revisit past disclosures as needed.
Pliant Therapeutics, Inc. (Nasdaq: PLRX) announced its data presentation on PLN-74809 during the ATS 2020 Virtual Sessions on Sept. 24, 2020. PLN-74809 is an oral dual selective integrin inhibitor being evaluated for treating fibrotic diseases like idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The treatment has received Orphan Drug Designation by the FDA for both indications and is currently in Phase 2a trials for IPF and PSC. The presentation will be accessible to registered attendees until Nov. 10, 2020.
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology firm specializing in fibrosis treatments, will participate in investor conferences during September 2020. Key events include Citi's 15th Annual BioPharma Conference from September 8-11, where Scott Turner, Ph.D., will discuss COVID-19 therapeutics on September 9 at 9:50 a.m. EDT. Additionally, the company will attend Cantor Fitzgerald's Virtual Global Healthcare Conference from September 15-17. More details and access to presentations can be found on the Pliant Therapeutics Investors page.
Pliant Therapeutics, Inc. (Nasdaq: PLRX) announced its participation in The Digital International Liver Congress 2020, showcasing data on PLN-74809 for treating fibrotic diseases like idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The oral presentation highlights PLN-74809 as a dual integrin inhibitor that reduces fibrosis in preclinical models. Additionally, a poster presentation will discuss collagen gene expression reduction in liver tissue from cirrhotic patients. Pliant is in Phase 2a trials for PLN-74809 and is also developing PLN-1474 for liver fibrosis related to nonalcoholic steatohepatitis (NASH).
Pliant Therapeutics, Inc. (PLRX) reported strong progress in its fibrosis treatment pipeline, highlighting the initiation of a Phase 2a trial for PLN-74809 in idiopathic pulmonary fibrosis, along with advancements in its partnership with Novartis for PLN-1474. The company completed a successful IPO, raising $165.6 million, with an additional $10 million from Novartis. Financial results showed second-quarter related party revenue of $3.6 million and a net loss of $17 million. Pliant holds $312.5 million in cash, ensuring operational stability through 2023.